Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated ...

Accounting for around one-quarter of Europe's market cap, the GRANOLAS members are: GSK (GSK) (UK:GSK), Roche (CH:ROG), ASML (ASML) (NL:ASML), Nestlé (CH:NESN) (NSRGY), Novartis (NVS) (CH:NOVN), Novo ...

The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.